We are collaborating on clinical trials for a new treatment for this sometimes fatal common infection
Strongyloidiasis is a soil-transmitted helminth infection caused by strongyloides stercoralis. The WHO estimates that up to 100 million people, particularly children, are infected with this parasitic worm. The causative worm has a different lifecycle from other soil-transmitted helminths and infection can be fatal.
people, particularly children, are infected
public health strategies for controlling this disease are active at the global level
World Health Organization. Ending the neglect to attain the Sustainable Development Goals: A road map for neglected tropical diseases.
World Health Organization. WHO Strongyloidiasis fact sheet.
Children are particularly vulnerable to this infection
Treatment options are limited, with ivermectin, an anti-parasitic, being the medicine of choice, while other anthelmintic medicines such as albendazole and mebendazole, which limit the parasite’s absorption of sugar, lack sufficient efficacy as a single dose.
MDGH is collaborating in clinical trials of moxidectin as a treatment for strongyloidiasis in Cambodia and Laos led by the Swiss Tropical and Public Health Institute, Switzerland.
A paediatric dose-finding study, a phase 3b trial comparing efficacy and safety of annual and biannual moxidectin or ivermectin treatment and mathematical modelling of moxidectin and ivermectin based elimination strategies to support country policy decisions.
Developing a paediatric formulation moxidectin for neglected infectious diseases.
A painful and debilitating disease of the lymph system affecting over 50 million people at any one time.
A soil-transmitted infection affecting up to 100 million people, particularly children.
A chronic infectious disease which may cause skin lesions and nerve damage found in 127 countries.